Skip to main content
Skip to main content
Company
Management Team
Board of Directors
Scientific Advisory Board
Partnerships
Contact Us
Pipeline
Indications
Science
Galinpepimut-S: WT1 Targeting Immunotherapeutic
SLS009: Highly Selective CDK9 Inhibitor
Publications
Clinical Trials
Ongoing
Completed
Investors
Overview
News
Events & Presentations
Stock Information
Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
Careers
WT1 Antigen ranked by National Cancer Institute as a top priority for immunotherapy
Learn More
Media Coverage
Home
Overview
Company
About SELLAS
Management
Board of Directors
Scientific Advisory Board
Partnerships
Contact
Sellas Pipeline
Indications
Galinpepimut-S (GPS) Therapy
Our Therapy
Wt1 Cancer Immunotherapy
Wt1 Immunotherapy Development
News
Pipeline
NELIPEPIMUT-S (NPS) Clincal Trials
Anagrelide CR Clinical Trials
Events & Presentations
Publications
Galinpepimut-S (GPS)
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
Indications
Analyst Coverage
Financials
Investors
Media Coverage
SEC Filings
Corporate Governance
Management
Board of Directors
Governance Documents
Committee Composition
Board Diversity Matrix
Investor Resources
Contact IR
Investor FAQs
Whistleblower
Information Request
Email Alerts
Derivative Litigation
Careers
Shareholder Letter
7 Times Square, Suite 2503
New York, NY 10036
646-200-5278
info@sellaslife.com
Company
About SELLAS
Management Team
Board of Directors
Scientific Advisory Board
Partnerships
Contact Us
Pipeline
Indications
Science
Galinpepimut-S: WT1 Targeting Immunotherapeutic
SLS009: Highly Selective CDK9 Inhibitor
Publications
Clinical Trials
Ongoing
Completed
Investors
Careers
Privacy Policy
Terms
Sitemap
©
SELLAS Life Sciences Group Inc. All Rights Reserved